Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy

(2020) Arsela Prelaj et al.   Clinical Lung Cancer

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

(2020) Shirish Gadgeel et al.   JOURNAL OF CLINICAL ONCOLOGY

Deciphering the tumor microenvironment through radiomics in non-small cell lung cancer: Correlation with immune profiles

(2020) Hyun Jung Yoon et al.   PLoS One

Overall survival prediction of non-small cell lung cancer by integrating microarray and clinical data with deep learning

(2020) Yu-Heng Lai et al.   Scientific Reports

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies

(2020) Florent Petitprez et al.   Frontiers in Immunology

Development and Validation of a 12-Gene Immune Relevant Prognostic Signature for Lung Adenocarcinoma Through Machine Learning Strategies

(2020) Liang Xue et al.   Frontiers in Oncology

A “Third Wheel” Effect in Health Decision Making Involving Artificial Entities: A Psychological Perspective

(2020) Stefano Triberti et al.   Frontiers in Public Health

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407

(2020) Luis Paz-Ares et al.   Journal of Thoracic Oncology

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker

(2020) Bingxi He et al.   Journal for ImmunoTherapy of Cancer

Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system

(2020) Arsela Prelaj et al.   Translational Lung Cancer Research

Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier

(2020) Zhihao Lu et al.   Journal for ImmunoTherapy of Cancer

Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma

(2020) Paul Johannet et al.   CLINICAL CANCER RESEARCH

Circulating microRNAs and PD-L1 tumor expression are associated with survival in advanced NSCLC patients treated with immunotherapy: a prospective study

(2019) Mattia Boeri et al.   CLINICAL CANCER RESEARCH

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

(2019) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2019) D Planchard et al.   ANNALS OF ONCOLOGY

Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for non-small cell lung cancer: pooled analysis of clinical trials.

(2019) Michael J. Sorich et al.   Journal of Thoracic Oncology

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

(2019) Martin Reck et al.   EUROPEAN JOURNAL OF CANCER

Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non–Small Cell Lung Cancer

(2019) Mohammadhadi Khorrami et al.   Cancer Immunology Research

Advanced Deep Learning Embedded Motion Radiomics Pipeline for Predicting Anti-PD-1/PD-L1 Immunotherapy Response in the Treatment of Bladder Cancer: Preliminary Results

(2019) Rundo et al.   Electronics

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

(2018) Scott Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

(2018) Roberto Ferrara et al.   JAMA Oncology

Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer

(2018) Arsela Prelaj et al.   EUROPEAN JOURNAL OF CANCER

Circulating mir-320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk

(2018) Orazio Fortunato et al.   INTERNATIONAL JOURNAL OF CANCER

Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

(2018) Giuseppe Lo Russo et al.   CLINICAL CANCER RESEARCH

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond

(2017) Lee Pai‐Scherf et al.   ONCOLOGIST

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening

(2017) Mavis Mensah et al.   Jove-Journal of Visualized Experiments

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

(2015) A. Sivan et al.   SCIENCE

Clinical Utility of a Plasma-Based miRNA Signature Classifier Within Computed Tomography Lung Cancer Screening: A Correlative MILD Trial Study

(2014) Gabriella Sozzi et al.   JOURNAL OF CLINICAL ONCOLOGY

MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer

(2011) Mattia Boeri et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA